Soligenix Announces Two-Year Thermostable Ebolavirus Vaccine Stability Data
TL;DR
Soligenix's ThermoVax platform gives a strategic edge by enabling stable ebolavirus vaccines without cold-chain, reducing costs and boosting distribution efficiency in pandemic response.
Soligenix's ThermoVax technology stabilizes protein subunit vaccines at up to 40°C for two years, using heat-resistant formulation to maintain potency and simplify storage logistics.
Soligenix's thermostable vaccines improve global health equity by enabling reliable distribution to remote areas, enhancing pandemic preparedness and saving lives in underserved communities.
Soligenix's ebolavirus vaccines achieve 100% protection in primates and remain potent after two years at high temperatures, a breakthrough in vaccine stability science.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. (NASDAQ: SNGX) has published new data showing that its ebolavirus vaccines developed with the ThermoVax platform maintain full potency after two years of storage at temperatures up to 40°C (104°F). The bivalent and trivalent vaccines, formulated from Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus antigens, demonstrated robust immune responses in animal models with up to 100% protection in non-human primates.
The research, conducted in collaboration with Dr. Axel Lehrer at the University of Hawaiʻi at Mānoa, represents a significant advancement in vaccine technology. ThermoVax enhances protein subunit vaccines—considered the gold standard for safety—by eliminating cold-chain requirements that have historically limited vaccine distribution in resource-constrained regions and during public health emergencies.
The extended stability data, published in the journal Vaccine, addresses one of the most critical challenges in global health: maintaining vaccine efficacy in tropical climates and remote areas without reliable refrigeration. This breakthrough could transform how vaccines are distributed during outbreaks of deadly hemorrhagic fevers like Ebola and Marburg virus diseases, which typically occur in regions with limited infrastructure.
Soligenix's Public Health Solutions business segment, which includes this vaccine program, has been supported by government funding from the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority. The company maintains its newsroom at https://ibn.fm/SNGX where investors can access the latest updates.
The thermostable vaccine technology could have far-reaching implications for pandemic preparedness, enabling stockpiling of effective vaccines without the massive logistical challenges and costs associated with cold storage. This development comes at a critical time when global health organizations are seeking more resilient vaccine distribution systems to respond to future infectious disease threats.
Curated from InvestorBrandNetwork (IBN)
